FAILURE OF AXONAL TRANSPORT INDUCES A SPATIALLY COINCIDENT INCREASE IN ASTROCYTE BDNF PRIOR TO SYNAPSE LOSS IN A CENTRAL TARGET

S. D. CRISH, J. D. DAPPER, S. E. MACNAMEE, P. BALARAM, T. N. Sidorova, W. S. LAMBERT AND D. J. CALKINS

a The Vanderbilt Eye Institute, Vanderbilt University Medical Center, 11425 Langford Medical Research Building IV, 2213 Garland Avenue, Nashville, TN 37232, USA
b Vanderbilt Brain Institute, Vanderbilt University Medical Center, U1205 Medical Research Building III, 465 21st Avenue South, Nashville, TN 37232, USA

Abstract—Failure of anterograde transport to distal targets in the brain is a common feature of neurodegenerative diseases. We have demonstrated in rodent models of glaucoma, the most common optic neuropathy, early loss of anterograde transport along the retinal ganglion cell (RGC) projection to the superior colliculus (SC) is retinotopic and followed by a period of persistence of RGC axon terminals and synapses through unknown molecular pathways. Here we use the DBA/2J mouse model of hereditary glaucoma and an acute rat model to demonstrate that retinotopically focal transport deficits in the SC are accompanied by a spatially coincident increase in brain-derived neurotrophic factor (BDNF), especially in hypertrophic astrocytes. These neurochemical changes occur prior to loss of RGC synapses in the DBA/2J SC. In contrast to BDNF protein, levels of Bdnf mRNA decreased with transport failure, even as mRNA encoding synaptic structures remained unchanged. In situ hybridization signal for Bdnf mRNA was the strongest in SC neurons, and labeling for the immature precursor pro-BDNF was very limited. Subcellular fractionation of SC indicated that membrane-bound BDNF decreased with age in the DBA/2J, while BDNF released from vesicles remained high. These results suggest that in response to diminished axonal function, activated astrocytes in the brain may sequester mature BDNF released from target neurons to counter stressors that otherwise would challenge survival of projection synapses.

Key words: neurodegeneration, axonal transport, glaucoma, astrocytes, superior colliculus, brain-derived neurotrophic factor.

INTRODUCTION

Most neurodegenerative disorders involve early signs of axonal dysfunction, including diminished active transport to and from major projection targets in the brain (Adalbert et al., 2009; Morfini et al., 2009). The same is so of the optic neuropathies, the most common of which is glaucoma. Glaucoma is the leading cause of irreversible blindness worldwide and is characterized by progressive degeneration of the retinal ganglion cell (RGC) projection to the brain (Nickells, 1996; Quigley, 1999; Quigley and Broman, 2006; Kwon et al., 2009; Susanna, 2009; Crish and Calkins, 2011). Age and sensitivity to intraocular pressure (IOP) are important risk factors for the disease (Gordon et al., 2002), so animal models that incorporate these are most useful.

The DBA/2J inbred mouse model of hereditary glaucoma presents age-dependent variations in IOP due to mutations that affect fluid flow in the anterior eye (Dangias et al., 2003; Schuettauf et al., 2004; Jakobs et al., 2005; Zhou et al., 2005; Inman et al., 2006; Howell et al., 2007). Failure of axonal transport is among the earliest events in the DBA/2J, preceding both degeneration in the optic nerve and RGC somatic loss in the retina (Buckingham et al., 2008; Chidlow et al., 2011; Calkins, 2012). Deficits in anterograde transport from the retina appear earliest at the most distal RGC projection site in the superior colliculus (SC) and progress to more anterior sites over time (Crish et al., 2010). The SC is the primary target for RGC axons in the rodent brain (Hofbauer and Drager, 1985), and a robust complement of RGC axon terminals and their post-synaptic neurons persist there long after transport is completely depleted, which we have described quantitatively (Crish et al., 2010).
Both in the DBA/2J and an inducible model, deficits in anterograde transport progress from one retinotopic sector of the SC to the next (Crish et al., 2010), much like the progression of vision loss in human glaucoma (Goldblum and Mittag, 2002). Age is the predominant determinant of transport depletion, with elevated IOP as an additional stressor that biases the system toward dysfunction (Crish et al., 2010). The sectorial pattern of transport loss in the SC is similar to markers for RGC somatic and axonal pathology in animal models and to topographical loss of RGCs in human glaucomatous retinas (Jakobs et al., 2005; Schlamp et al., 2006; Reichstein et al., 2007; Lei et al., 2009).

Interestingly, we found that even well after axonal transport to the SC is completely depleted, key synaptic structures in the RGC projection persist (Crish et al., 2010). Neural targets in the brain respond to degenerative stressors like diminished transport with mechanisms thought to aid in the retention and/or recovery of afferent input that may include remodeling to compensate for loss (Kimura et al., 2006; Endo et al., 2007; Hennigan et al., 2007; Song et al., 2008). For example, after NMDA-induced excitotoxic RGC loss, both brain-derived neurotrophic factor (BDNF) and the astrocytic marker glial fibrillary acidic protein (GFAP) increase within the retinal recipient zone of the SC (Tanaka et al., 2009). Increases in target site BDNF may occur prior to overt degeneration in Alzheimer’s disease (Kimura et al., 2004), leading us to question if a similar mechanism is at play within the SC in response to transport failure induced by glaucomatous injury.

**EXPERIMENTAL PROCEDURES**

**Animals**

DBA/2J and its transgenic control strain D2-Gpnmb<sup>−/−</sup> (Howell et al., 2007) were obtained along with C57BL/6 mice from Jackson Laboratories (Bar Harbor, ME, USA). All experimental procedures were approved by The Vanderbilt University Medical Center Institutional Animal Care and Use Committee. Animals were maintained in a 12-h light–dark cycle with standard rodent chow available ad libitum. We measured IOP in a subset of DBA/2 mice up to 10 months of age using the Tono-Pen XL (Medtronic Solan, Jacksonville, FL, USA) as described previously (Inman et al., 2006).

**Microbead occlusion model**

To induce elevation of IOP in the rat eye, we utilized microbead occlusion as described (Sappington et al., 2009; Crish et al., 2010). Baseline IOP measurements were obtained in awake behaving rats for at least 2 consecutive days prior to microbead surgery using the Tono-Pen XL (Medtronic Solan). Experimental IOP readings began 24 h post-microbead surgery and continued daily until termination of the experiment. To inject microbeads, animals were anesthetized with 2.5% isoflurane using an anesthesia system (VetEquip, Inc., Pleasanton, CA, USA). Mice received an intravitreal injection of 1 μl of a 1% solution of cholera toxin subunit β (CTB) conjugated to Alexa Fluor 594 (Invitrogen, Carlsbad, CA, USA) or Alexa Fluor 488 (Invitrogen). Forty-eight hours later animals were deeply anesthetized with an overdose of Nembutal (200 mg/kg, Henry Schein, Inc., Indianapolis, IN) and perfused intracardially with phosphate-buffered saline (PBS) followed by 4% paraformaldehyde in PBS. Brains were removed and cryoprotected in 30% sucrose overnight and 50-μm coronal slices were taken on a freezing sliding microtome. CTB signal in serial SC sections was digitally photographed on an Olympus AX-70 microscope and intensity of label quantified using ImagePro (Media Cybernetics, Bethesda, MD, USA), as previously described (Crish et al., 2010). Label density from every other section was combined into a colorimetric representation of CTB signal across the collicular retinotopic map (Lambert et al., 2011).

**Immuo-chemistry**

Immuno-labeling of brain sections was performed as described previously (Sappington et al., 2009; Crish et al., 2010). We used an antibody against BDNF that strongly recognizes the internal domain of the mature form of the protein and with lesser affinity the immature form (BDNF N-20, 1:200, sc-546, Santa Cruz Biotechnology, Santa Cruz, CA, USA; Tongiorgi et al., 2004). Immature BDNF was detected using an antibody specific for pro-BDNF (1:100, sc-65513, Santa Cruz Biotechnology). Antibodies against estrogen-related receptor β (ERRβ, 1:500, E0156, Sigma–Aldrich, St. Louis, MO, USA) and vesicular glutamate transporter 2 (VGluT2, 1:500, 135403, Synaptic Systems, Gottingen, Germany) were used to visualize the RGC axonal projection and axon terminals as described (Crish et al., 2010). Monoclonal antibodies against GFAP (1:500, MAB360, Millipore, Temecula, CA) and phosphorylated heavy chain neurofilament (bNf) (SMI-31, 1:1000, SMI-31R, Covance, Emeryville, CA, USA) was used to identify astrocytes and SC neurons and processes (Wims and Bahr, 1995), respectively. Wide-field fluorescent images were taken on an Olympus AX-70 microscope. Confocal images were taken using a Zeiss LSM510 Meta upright confocal microscope. Photomicrographs were analyzed using a custom-written macro in ImagePro (Media Cybernetics) that determined the percent area of the positive label.

**Transmission electron microscopy**

Animals were perfused as described above with the addition of 2% glutaraldehyde to the fixative. Brains were removed and 125-μm<sup>3</sup> samples containing the SC were dissected and embedded in Epon resin as described previously (Yao et al., 2002; Calkins et al., 2005). Ultrathin sections were taken and imaged on a Philips EM-12 Transmission Electron Microscope.
Differential transport in SC: micro-dissection and quantitative PCR (qPCR)

Intravitreal CTB injections were performed in eight DBA/2J mice between the ages of 5 and 11 months as described above. After 48 h, animals were euthanized by cervical dislocation, the brain was removed, and cortexoverlayingthe SC was dissected away to expose the midbrain. The SC layers containing RGC projections and their terminals were separated from the deeper SC and immersed in RNAlater (Ambion, Austin, TX, USA). Within 3 min, each superficial SC (sSC) was flat-mounted on a slide, viewed under an Olympus AX-70 microscope and micro-dissected into areas with (intact) and without (depleted) CTB label. From these animals, we identified 10 individual SC suitable for RNA extraction.

The two micro-dissected samples (intact and depleted CTB) from each SC were RNA-extracted as previously described (Hanna and Callkins, 2006). Briefly, after overnight incubation in lysis buffer (10 mM Tris/HCl, pH 8.0; 0.1 mM EDTA, pH 8.0; 2% SDS, pH 7.3; and 500 μg/ml proteinase K (Clontech Labs, Mountain View, CA, USA)), RNA was extracted using Trizol reagent (Invitrogen) with 10 μg of glycogen added as an RNA carrier prior to precipitation. RNA concentration and purity were determined using a NanoDrop 8000 spectrophotometer (Thermo Scientific, Wilmington, DE, USA). Samples (1 μg) were DNase treated (Invitrogen) prior to cDNA synthesis (Applied Biosystems reagents, Foster City, CA, USA), and qPCR was performed using an ABI PRISM 7300 Real-Time PCR System and FAM dye-labeled gene-specific probes for Bdnf, calcium/calmodulin-dependent protein kinase type II alpha (Camk2a), c-fos, dynactin (Dctn), GFAP, Syn1, and Tau (Applied Biosystems). Cycling conditions and cycle threshold values were automatically determined by the supplied ABI software ( SDS v1.2). Relative product quantities for each transcript were performed in triplicate, normalized to 18s rRNA as an endogenous control, and determined using the 2^-DDCT analysis method (Livak and Schmittgen, 2001). Data are presented as the ratio of gene expression was calculated relative to 18s rRNA in triplicate for each sample, as described above.

For whole-tissue qPCR, RNA was extracted as described from the retina, myelinated optic nerve, and SC from each of five C57BL/6 animals (3 months). The two retinas, nerves and SC from each animal were pooled as a single sample. Bdnf expression was calculated relative to 18s rRNA in triplicate for each sample, as described above.

Fluorescent in situ hybridization

To generate Bdnf probes, total RNA from C57BL/6 mouse brain was extracted using RNeasy Mini Kit (Qiagen Inc., Valencia, CA, USA) and first-strand cDNA synthesis performed using Superscript III reverse transcriptase (Invitrogen). Antisense probes for Bdnf mRNA were made against a nucleotide sequence present in all splice variants of mouse Bdnf (nucleotides 326–750 of [GenBank: NM_001048142]) using a NanoDrop spectrophotometer. Probes were stored at −80 °C.

Mice were perfused and coronal sections (50 μm) taken as described above (see “Immunohistochemistry” section). Tissue was washed in 0.75% glycine followed by 0.3% Triton X-100, and then treated with 1 μg/ml proteinase K (Sigma–Aldrich) at room temperature for 5 min. Sections were acetylated in 0.25% acetic anhydride/0.1 M triethanolamine (pH 8.0) for 10 min and rinsed. Tissue was pre-hybridized for 1 h at 58 °C in hybridization solution (50% formamide, 5 × SSC, 2% blocking reagent (Roche), 0.1% N-lauroylsarcosine (NLS) (Sigma–Aldrich) and 0.1% SDS). Probes (2 ng/ml) were denatured at 80 °C for 10 min in hybridization solution prior to incubation with brain sections at 58 °C overnight. Tissue was then washed and treated with 20 μg/ml RNase A (Macherey-Nagel, Bethlehem, PA, USA) in 10 mM Tris (pH 8.0), 1 mM EDTA and 0.5 M NaCl for 10 min at 37 °C to remove excess probe. Immunodetection of labeled BDNF mRNA was performed using anti-DIG-Fab-POD conjugate (Roche) diluted 1:100 in blocking buffer (1% blocking reagent (Roche) in 0.1 M Tris (pH 7.5), 0.15 M NaCl) followed by detection using the TSA plus Fluorescein system (Perkin-Elmer, Boston, USA). Immuno-labeling was performed with antibodies to GFAP (1:500, 20334, DAKO, Carpinteria, CA) and pNF (1:1000, SMI-31) as described above. Confocal images were taken using an Olympus FV-1000 inverted confocal microscope.

Subcellular fractionation and western blotting

We performed subcellular fractionation of the homogenate obtained from the superficial region of the DBA/2J SC as described previously with minor modifications (Huttner et al., 1983; Blackstone et al., 1992; Fawcett et al., 1997). The superficial layer of the SC was dissected from the fresh DBA/2J brain and immediately immersed into HEPES-buffered sucrose (0.32 M sucrose, 4 mM HEPES, pH 7.4, 0.1 mM phenylmethanesulfonyl fluoride, 1 mM benzamide-HCl, 2 mM EGTA, 1 mM sodium fluoride, and 50 mM sodium carbonate) containing protease and phosphatase inhibitors (Roche Diagnostics, Indianapolis, IN, USA). Tissue was homogenized and then centrifuged for 10 min at 1000 × g to remove nuclei and large debris and then for 15 min at 10,000 × g to yield a light plasma membrane pellet consistent with synaptosome isolation. For lysis, this pellet fraction was resuspended in ice cold water containing protease and phosphatase inhibitors, homogenized and then adjusted to 4 M HEPES and pH 7.4 with 0.1 M HEPES–NaOH. Following 30-min incubation on ice, the suspension was centrifuged at 25,000 × g for 20 min to yield the lysed light-membrane pellet (LP3) and a crude vesicle supernatant fraction, which was then centrifuged at 165,000 × g for 2 h to yield a supernatant of released vesicle content (LS4) and a vesicle-enriched pellet (P4). Samples of fractions LP3, LS4 and P4 containing approximately 40 μg of protein were separated on 15% Tris–HCl Criterion gel (Bio-Rad, Hercules, CA, USA) by SDS–PAGE using standard SDS sample buffer containing 0.1 M dithiothreitol. Proteins were transferred onto PVDF membranes (Immobilon–FL, Millipore) and blots were probed with antibodies against the synaptic vesicle membrane protein synaptotagmin I (1:750, Acris Antibodies Inc., San Diego, CA, USA), BDNF (N-20) (1:200, Santa Cruz), and β-actin (1:2000, Ambion).

RESULTS

Focal increases in BDNF with transport loss

Previously we demonstrated that deficits in anterograde transport to the DBA/2J SC progress in retinotopic sectors and increase in likelihood and severity with age; age-dependent elevation in IOP is an additional stressor but not the primary predictor (Crish et al., 2010). The SC from the C57BL/6 (C57) and D2-Gpmb+ non-glaucomatous mouse strains and a 3-month DBA/2J exhibited intact CTB signal across the sSC (Fig. 1A). This is reflected in the complete retinotopic...
representation of CTB signal for these SCs (Fig. 1A, insets). In contrast, SC from 8-, 10- and 12-month DBA/2J mice demonstrated increasingly depleted CTB signal indicating diminished anterograde transport (Fig. 1B). For these, transport depletion followed a sectorial progression filling from the peripheral field to the representation of the optic disk gap (Fig. 1B), consistent with our published observations (Crish et al., 2010).

Next we tested whether depletion of transport signal was accompanied by changes in the levels of BDNF, as has been described for the SC with NMDA-induced RGC loss (Tanaka et al., 2009). In the normal C57 SC, BDNF immuno-labeling was the strongest in the deep layers of the SC, with only sporadic signal in the superficial layers where RGC axons terminate. Co-localization of BDNF with transported CTB was not detected in the sSC (Fig. 2A). In a 3-month DBA/2J, BDNF label remained uniform in the deep SC, like the C57, but increased in the RGC-recipient zone coincident with a focal transport deficit near the midline (Fig. 2B). Across ages of DBA/2J, BDNF localization increased focally wherever CTB signal in the sSC was depleted (Fig. 2C, D). Even as BDNF levels rose in the RGC-recipient zone, levels in the deeper layers remained the same (Fig. 2D). In removing the cortex during dissection, often we retained a sharp delineation of the dorsal border of superficial layer 1 of the SC, which is primarily astrocytic (Harvey et al., 1993). This border was generally marked by strong BDNF localization (Fig. 2B, C).

The coincident increase in BDNF with transport loss was not confined to the DBA/2J. Previously we demonstrated that deficits in anterograde transport to the SC similar to those in the DBA/2J could be induced by elevating IOP in the rat eye by injection of inert microspheres into the anterior chamber (Crish et al., 2010). Here, over a 5-week-period microbead injection elicited a 35% elevation in IOP compared to IOP in the opposing eye, which received an equivalent volume injection of saline (Fig. 3A; p < 0.001). This elevation induced a focal deficit in CTB transport (Fig. 3B, left panel), similar to the sectorial depletion we previously described in this model (Crish et al., 2010). As in the DBA/2J, loss of transport was accompanied by increased BDNF in the sSC, spatially coincident with the region of diminished CTB signal (Fig. 3B, right panels). For areas with intact transport, most BDNF was contained in the deeper SC, as in the DBA/2J (Fig. 2).

**Hypertrophy of BDNF-containing astrocytes**

In the DBA/2J SC, BDNF levels remained modest in the RGC-recipient zone if CTB signal was intact, even if elsewhere in the SC transport was depleted (Fig. 4A). Thus, changes in BDNF were mostly restricted in terms of spatial distribution. With loss of CTB signal, the increase in BDNF appeared at least in part to originate in astrocyte processes, especially those encroaching the RGC-recipient zone from the dorsal ridge (Fig. 4B). For a 10-month DBA/2J, complete depletion of CTB signal was accompanied by hypertrophy of BDNF-expressing astrocytes labeled by GFAP along the midline separating the SC for the left and right optic projections (Fig. 4C). This same transport-depleted SC demonstrated even more profound hypertrophy of astrocytes labeled for BDNF along the dorsal ridge containing layer 1 (Fig. 4D). Even with increased astrocyte BDNF, it was most abundant in the underlying neuropil of the SC.

---

**Fig. 1.** Anterograde transport to the mouse superior colliculus. Micrographs of the superior colliculus (SC) in cross-section (coronal plane) following intravitreal injections of cholera toxin β (CTB). (A) SC of C57BL/6 (C57), D2-Gpnmb+ , and a 4-month DBA/2J each demonstrate intact CTB signal (green). Dashed line demarcates the retinal recipient zone in the superficial SC (sSC) from the deep (dSC). (B) SC from an 8-month DBA/2J (left) shows a focal deficit (arrowheads), while a 10-month (middle) has only residual signal (bracket) and a 12-month (right) has complete depletion. Insets show retinotopic map reconstructed from serial sections through each SC with representation of optic disk gap (circle). Signal density ranges from 100% (red) to 50% (green) to 0% (blue) (Crish et al., 2010). Average lifetime IOP for the 4-, 8- and 10-month DBA/2J is indicated. Scale = 500 μm. (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.)
Compared to C57, regions of the DBA/2J SC with intact CTB signal demonstrated both increased BDNF (67%) and GFAP (51%), though neither difference was significant (Fig. 4E; \(p = 0.061\) and \(0.187\), respectively). In regions of the DBA/2J SC with depleted transport, BDNF increased 120% and GFAP 239% compared to the C57 (\(p < 0.001\)) and by 32% (BDNF, \(p = 0.027\)) and 124% (GFAP, \(p < 0.001\)) compared to regions of the same SC with intact CTB transport (Fig. 4E).

Confocal images of a single thin plane through the 10-month DBA/2J SC shown in Fig. 4C suggest that astrocyte BDNF was largely cytoplasmic in origin and distributed nearly uniformly throughout the astrocyte (Fig. 5A). In a higher magnification single plane through an 8-month DBA/2J SC, BDNF appeared to distribute in pockets of focal concentration within the astrocyte (Fig. 5B). In orthogonal views of this plane, BDNF clearly was internalized and not generally associated with the astrocyte membrane. Finer astrocyte processes including end-feet near SC neuronal processes did not appear to contain appreciable amounts of BDNF (Fig. 5B, side images).

In SC with intact CTB transport, GFAP-labeled astrocytes were most prominent along the dorsal ridge of superficial layer 1 (Fig. 6A). The retinal recipient zone of the sSC itself contained relatively low levels of GFAP,
as did the deep SC, which contains a visual map but lacks a direct retinal projection. GFAP label along the midline between the two SCs distributed evenly, reflecting the symmetry in intact CTB signal (Fig. 6A, right panel). An 8-month DBA/2J with intact transport in one SC and a near-complete depletion in the other demonstrated a unilateral increase in GFAP label and astrocyte hypertrophy in both the superficial and deep SC (Fig. 6B). These changes were coincident with transport loss, but prior to overt degeneration. A 10-month SC with no remaining CTB signal and considerable astrocyte hypertrophy in the superficial recipient zone retained an intact distribution of RGC axon terminals visualized either with antibodies against ERRβ (Fig. 6C) or VGluT2 (Fig. 6D). Both ERRβ and VGluT2 labeling indicate persistence of RGC axons and their terminals in the DBA/2J SC, which are retained nearly in toto up to 22 months, long after complete depletion of anterograde transport at 11–12 months; this is quantified extensively in our previous work (Crish et al., 2010).

This structural persistence is reiterated at the ultrastructural level in electron micrographs (Fig. 7). For...
A 12-month SC organization was completely intact (Fig. 7A), and we identified the axon terminals from RGCs (RLP), inhibitory intracollicular terminals (F), and cortico-collicular projections (RSD) based on established morphological criteria (Valverde, 1973; Calkins et al., 2005). The 12-month SC included clear synaptic active zones between RLP terminals and the dendrites of collicular relay neurons (Fig. 7A). For a 15-month SC, RLP terminals remained intact and formed pre-synaptic active zones, but appeared slightly dystrophic (Fig. 7B). This is consistent with our earlier work in which we quantified persistence of SC synaptic structures for a limited interval after anterograde transport depletion (see Fig. 7 in Crish et al., 2010).

Changes in gene expression with loss of anterograde transport

We used qPCR to measure changes in gene expression associated with the loss of anterograde transport. Under fluorescent illumination, we micro-dissected RGC-receptor regions with depleted CTB signal vs. regions

---

**Fig. 5.** Localization of BDNF within astrocytes. (A) High magnification of single-plane (1.5 μm thick) through the midline between the two SCs from the 10-month DBA/2J shown in Fig. 4C. Image shows apparent localization of BDNF within GFAP-labeled hypertrophic astrocyte processes (arrowheads). (B) Single-plane (1.5-μm-thick) image of a GFAP-labeled astrocyte near the dorsal ridge of an 8-month DBA/2J SC (left panel). End-on (orthogonal) view of the same plane for both the Y (right panel) and X (left panel) axes illustrates location in tissue of the image plane (dotted blue lines) and of center of the astrocyte (dotted white lines). While most BDNF distributes in the underlying neuropil, localization within the astrocyte forms diffusely distributed pockets within the cytoplasm (arrowheads). Smaller astrocyte processes, possibly end-feet, that are associated with neuronal processes appear to contain far less BDNF. Scale = 20 μm (A) or 10 μm (B). (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.)
Fig. 6. Astrocyte hypertrophy accompanies transport depletion and precedes structural loss. (A) An 8-month DBA/2J demonstrates intact CTB transport in both SC with modest GFAP label along the midline and dorsal ridge (right panel). (B) Another 8-month DBA/2J with intact CTB in one SC and only residual signal in the other (circled). With loss of CTB signal, GFAP-labeled astrocytes become hypertrophic throughout the SC (arrows). (C and D) Two 10-month DBA/2J SCs with completely depleted CTB signal (not shown) demonstrate persistence of the RGC axonal projection marker estrogen-related receptor beta (ERRβ, C) and RGC axon terminal marker vesicular glutamate transporter 2 (VGluT2, D). Both SC contain hypertrophic GFAP-labeled astrocytes (right panels). For both, boxed areas of higher magnification (bottom panels) show hypertrophic astrocytes in the RGC-recipient zone. Hypertrophy is also apparent in deeper SCs, as in B. Scale = 200 μm (A, B and C, D top panels) or 25 μm (C, D, bottom panels).

Fig. 7. Structural persistence following transport depletion. (A) Electron micrograph of sagittal section through superficial SC from a 12-month DBA/2J shows axon terminals from RGCs (RLP), intracollicular inhibitory neurons (F), and cortico-collicular projections (RSD) in proximity to a collicular relay neuron (dashed line) and dendrites (D). For definitions, see Calkins et al. (2005). Many terminals contain intact presynaptic active zones (arrowheads). (B) A 15-month DBA/2J colliculus also contains intact RLP terminals with some synapses to dendrites. Terminals near a degenerating RLP (*) appear slightly dystrophic.
with intact CTB (Fig. 8A, B). In completely intact SC, expression of Bdnf mRNA is several-fold higher than in the optic nerve and retina (Fig. 8C). Surprisingly, in the DBA/2J SC the ratio of Bdnf mRNA for depleted vs. intact transport was actually below unity, indicating a significant decrease in expression with transport loss (mean ratio of 0.658; \( p = 0.008 \)). Similarly, depleted transport was associated with significantly diminished expression of Dctn (ratio of 0.784, \( p = 0.0004 \)), a microtubule and dynein-binding protein involved in axonal transport. Expression of Tau also decreased with transport loss (0.746, \( p = 0.017 \)), suggesting changes in microtubule stabilization. The only genes with mean expression ratios greater than unity were Gfap (1.459) and c-fos (1.185), a marker for neural activity. However, both were highly variable between colliculi (\( p = 0.206 \) and 0.289, respectively).

As expected based on the persistence of RGC axon terminals (see “Hypertrophy of BDNF-containing astrocytes” section, Fig. 6C, D), the ratio for genes associated with synaptic structures did not change with transport loss and was close to unity. This was true for both the presynaptic protein synapsin (Syn1; ratio of 0.924) and its phosphorylating agent Camk2\(\alpha\) (ratio...
of 0.838). Levels of these genes were statistically similar between regions with and without transport ($p > 0.16$).

To confirm our RT-PCR results, we performed fluorescent in situ hybridization for Bdnf mRNA in conjunction with cell-specific markers. In C57 colliculus, Bdnf localization was clear in neurons labeled for pNF (Fig. 9A); a control sense sequence elicited no label as expected (Fig. 9B). The Bdnf transcript also localized within GFAP-expressing astrocyte cell bodies along the dorsal border of superficial layer 1; this was far less prominent in the retinorecipient zone of the sSC (Fig. 9A, C). A similar pattern was observed in 3-month DBA/2J (Fig. 9C). In 9-month DBA/2J mice, Bdnf signal appeared greatly diminished compared to both the C57 and 3-month DBA/2J (Fig. 9D), consistent with the PCR results (Fig. 8). Single plane images through the RGC-recipient layer revealed Bdnf localized to pNF$^+$ neurons enveloped heavily by astrocyte processes (Fig. 9E).

The apparent contradiction between increased BDNF protein and diminished Bdnf mRNA could be explained if the BDNF label actually represents detection of its immature form (pro-BDNF). However, in the C57 SC, antibodies specific for pro-BDNF elicit very little co-localized signal with GFAP-labeled astrocytes (Fig. 10A). Furthermore, in the RGC-recipient zone, most pro-BDNF was contained within small, irregular-shaped cells that resemble microglia. The exception was the dorsal border of the SC and the midline between the two colliculi, where a thin but intense band of co-localization with GFAP was observed. In both 8-month and 10-month DBA/2J SC (Fig. 9B, C), pro-BDNF did not localize in hypertrophic astrocytes but was most apparent in small cells whose morphologies we could not discern. Like the C57, co-localization was modest and restricted to the SC border and midline.

Finally, we performed western blots of subcellular fractions of the superficial layer of the DBA/2J SC to

---

**Fig. 9.** Bdnf mRNA in superior colliculus. (A) Bdnf antisense probe (red) heavily labeled collicular neurons expressing phosphorylated neurofilament (pNF, green) in the C57 colliculus. GFAP-expressing astrocytes (blue) lying adjacent to pNF$^+$ neurons along the dorsal border of superficial layer 1 also appeared to express Bdnf. A higher magnification view of the boxed area indicates intense co-localization of Bdnf and pNF. (B) Control Bdnf sense probe (red) elicits no label, as expected, in stacked images through C57 colliculus. pNF$^+$ cell bodies along border (arrowheads) are sheathed with astrocyte processes. (C) A 3-month DBA/2J colliculus demonstrates increased GFAP and similar pattern of Bdnf. GFAP$^+$ processes with Bdnf are less prominent than neuronal expression in the deeper layers of the superficial SC (arrowhead). (D) Bdnf expression decreases in 9-month DBA/2J colliculus with increased GFAP in astrocytes. A higher magnification shows confluence of astrocyte processes overlying Bdnf-expressing neuron (arrowhead). Images in A–D are stacked confocal planes. (E) Series of single plane images through colliculus shown in D illustrates astrocyte processes enveloping a Bdnf-expressing neuron (arrowheads). Scale = 50 μm (low magnification panels) or 20 μm (high magnification). (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.)
determine possible sources of BDNF, using detection of β-actin as a positive control (Fig. 11). As expected, detection of the synaptic vesicle protein synaptotagmin was most prominent in the synaptosomal membrane fraction (Fig. 11, left panel), but absent in the supernatant of released vesicle content (Fig. 11, right panel).
either by transport dysfunction or an associated event. and BDNF elevations could be triggered in concert to the SC progress retinotopically, like vision transport to the SC progress retinotopically, like vision glaucoma (microbead occlusion), deficits in axonal Buckingham et al., 2008; Crish et al., 1985). Both in the DBA/2J and an inducible model of within vesicles. synaptosomal fraction and completely absent in the vesicle membrane fraction. It was, however, highly concentrated in the released vesicle supernatant of BDNF was very low and decreased with age in the available pools during progression. In contrast, detection of BDNF within vesicles. Our current experiments demonstrate that BDNF increases focally in the retinorecipient region of the SC, coincident with areas of depleted transport of CTB (see “Focal increases in BDNF with transport loss” section, Figs. 2 and 3). BDNF signal increased both in neuronal processes and with increased GFAP in hypertrophic astrocytes (see “Hypertrophy of BDNF-containing astrocytes” section, Fig. 4). Thus, both GFAP and BDNF elevations could be triggered in concert either by transport dysfunction or an associated event. BDNF in astrocytes appeared to be internalized, largely within pockets reminiscent of endosomes (Fig. 5). While shrinkage and loss of retinal target neurons in the thalamus occur later in progression (Yucel and Gupta, 2008), we show that astrocyte hypertrophy coincides with transport depletion and precedes loss of synaptic structures or changes in the expression of synapse-related genes (see “Hypertrophy of BDNF-containing astrocytes” and “Changes in gene expression with loss of anterograde transport” sections, Figs. 6–8), paralleling other neurodegenerative diseases (Adalbert et al., 2009; Morfini et al., 2009). Coincident increases in BDNF and astrocyte hypertrophy might represent an intrinsic mechanism to ameliorate the progression of pathology or mitigate the effects of axon damage, as described in other systems (Kimura et al., 2006; Endo et al., 2007; Henningan et al., 2007; Song et al., 2008). NMDA-induced excitotoxicity in the retina also increases BDNF and GFAP in retinal brain targets (Tanaka et al., 2009); similar neurochemical changes in retinal targets occur in animal models utilizing acute elevations in ocular pressure (Sasaoka et al., 2008; Zhang et al., 2009). Thus, our finding suggests a more global mechanism for how retinorecipient targets respond to disease-relevant stressors.

The structural persistence following axonal dysfunction has profound implications for developing therapies. Restoring function to intact neuronal pathways is a much more tractable and attractive target for intervention than replacing neurons or long stretches of axons. We also observed a modest level of astrocyte hypertrophy with transport loss in the non-retinorecipient SC (see “Hypertrophy of BDNF-containing astrocytes” section, Fig. 6), which could be due to dysfunctional signaling from extra-retinal sources of visual input. As the retinotopic map is coarser in the deep SC, one would expect less topographical constraint in dysfunction-induced responses.

Expression of genes encoding synaptic structures in the SC remained unchanged with transport loss (see “Changes in gene expression with loss of anterograde transport” section, Fig. 8), consistent with a period of structural persistence (Fig. 6, Crish et al., 2010). However, expression of Bdnf mRNA diminished, as detected by both PCR (Fig. 8) and in situ hybridization (see “Changes in gene expression with loss of anterograde transport” section, Fig. 9). This decrease occurred in contrast to the obvious increase in BDNF protein with transport loss (see “Focal increases in BDNF with transport loss” and “Hypertrophy of BDNF-containing astrocytes” sections, Figs. 2–4). Disparities between levels of BDNF protein and mRNA have been reported in other models of neurodegeneration (Nawa et al., 1995; Lee et al., 2002), which may indicate a common neuronal response to injury.

Interestingly, the Bdnf anti-sense probe was detected most strongly within collicular neurons rather than astrocytes in the RGC-recipient zone (see “Changes in gene expression with loss of anterograde transport” section, Fig. 8), despite the latter’s high levels of BDNF protein. We designed our Bdnf anti-sense to recognize a nucleotide sequence common to all known splice variants of mouse Bdnf (see “Fluorescent in situ hybridization” section). Thus, our finding would seem to suggest that increased BDNF immuno-labeling in astrocytes was not due to de novo synthesis. It is possible that BDNF is undergoing increased translation in the SC despite limited gene expression or that the protein itself is being sequestered following limited translation thereby resulting in accumulation within astrocytes and collicular neurons. New experiments are necessary to test these ideas. Another possibility suggested by a recent study of the mouse hippocampus is the uptake by astrocytes of extracellular BDNF released from collicular neurons (Matsumoto et al., 2008). This seems plausible, since BDNF increased in the neuropil of the RGC-recipient zone with transport loss (see “Focal increases in BDNF with transport loss” and “Hypertrophy of BDNF-containing astrocytes” sections, Figs. 2–4). Astrocytes could then sequester external BDNF in response to diminished transcription in collicular neurons, possibly for re-release to strengthen synaptic structures (Lessmann et al., 2003; Bergami et al., 2008).
Another possibility suggested by the literature is that collicular neurons release pro-BDNF, which astrocytes would sequester, process and re-release as mature BDNF (Bergami et al., 2008; Yang et al., 2009). However, labeling with antibodies that specifically recognize pro-BDNF showed only modest signal in collicular neurons (see “Changes in gene expression with loss of anterograde transport” section, Fig. 10). This is meaningful especially when compared to the large number of SC neurons expressing Bdnf mRNA, as revealed by in situ hybridization (see “Changes in gene expression with loss of anterograde transport” section, Fig. 9). Moreover, GFAP-labeled astrocytes in the RGC-recipient zone did not contain pro-BDNF (see “Changes in gene expression with loss of anterograde transport” section, Fig. 10). Taken together, these results suggest that the BDNF signal we detected in astrocytes is not attributable to cross-reactivity with pro-BDNF. This is in agreement with careful control studies of the BDNF antibody we used that showed very low affinity for pro-BDNF (Tongiorgi et al., 2004).

Though BDNF was contained in the RGC-recipient zone of the SC, we observed little if any co-localization of BDNF protein within CTB-containing RGC axon terminals (see “Focal increases in BDNF with transport loss” and “Hypertrophy of BDNF-containing astrocytes” sections, Figs. 2 and 4). Results from the subcellular fractionation experiment indicate that synaptosomal membrane BDNF is relatively low in concentration and decreases in the SC with age (see “Changes in gene expression with loss of anterograde transport” section, Fig. 11). However, BDNF released from vesicles represents the highest fraction and does not change. In other brain regions, BDNF can be stored in and released from secretory dense-core vesicles (Dieni et al., 2012), with highly spatially specific exocytosis from both axonal and dendritic compartments in response to perturbations in neuronal activity (Dean et al., 2012). Thus, perhaps vesicle-stored BDNF in SC neurons is released in response to diminished RGC axonal transport and subsequent stress to synaptic activity.

Disruptions in neurotrophin signaling, including BDNF, have been extensively implicated in a variety of neurodegenerative diseases and traumatic injury (Oyesiku et al., 1999; Dougherty et al., 2000; Song et al., 2008; Zuccato and Cattaneo, 2009). It is presumed that intrinsically protective mechanisms must at some level utilize the actions of trophic factors, which now represent actively pursued therapeutic avenues (Zuccato and Cattaneo, 2009). Nevertheless, application or upregulation of BDNF has had limited success in animal models of Alzheimer’s, Parkinson’s, and Huntington’s diseases (Ando et al., 2002; Zuccato and Cattaneo, 2007), in spinal cord injury (McTigue et al., 1998), and in experimental autoimmune encephalomyelitis (De Santì et al., 2009). Similar to the results we report, a recent study demonstrated that over-expression of astrocyte-driven BDNF conserved striatal synaptic structures in a mouse model of Huntington’s disease (Giralt et al., 2011).

In the visual system, exogenous BDNF application to the eye exhibits only limited and temporary protection after optic nerve crush or transection (Di Polo et al., 1998; Chen and Weber, 2004; Parrilla-Reverter et al., 2009). Combined BDNF application to both the eye and brain is more effective in protecting RGCs, suggesting that targeting the brain may have potential therapeutic uses in eye diseases (Weber et al., 2010). In glaucoma, disrupted BDNF transport from the brain to the eye has been implicated in pathogenesis (Pease et al., 2000; Quigley et al., 2000), which is likely to include early degradation of axonal cytoskeleton at the optic nerve head (Chidlow et al., 2011). However, much like acute optic nerve injury, BDNF application to the glaucomatous eye has demonstrated limited capacity for neuroprotection (Ko et al., 2000; Ko et al., 2001). Given BDNF’s role in synaptic survival and neurite maintenance (Lessmann et al., 2003; Song et al., 2008), a better approach to realizing its therapeutic potential might be to link BDNF more directly to intrinsic mechanisms that contribute to persistence of RGC axonal structures following loss of active transport.

The current study did not address how deficits in axonal transport in the SC might modulate expression of the high-affinity tyrosine receptor kinase TrkB. Activation of TrkB by BDNF affects several intracellular cascades that influence neuronal repair and survival, and so modulation of the receptor is of interest from a therapeutic standpoint (Fenner, 2012). The truncated isoform of TrkB, TrkB.B11, is also widely distributed throughout the brain and is expressed not only in neurons, but in different populations of astrocytes (Ohira et al., 2005). Most importantly, from the standpoint of this study, TrkB.B11 is thought to sequester and internalize BDNF for later release. In hippocampal astrocytes, TrkB.B11 at the plasma membrane was shown to bind BDNF from the extracellular domain and mediate its endocytosis prior to release into the extracellular space (Alderson et al., 2000). This pathway could ostensibly contribute to focal sequestration and re-release of BDNF from astrocytes in response to depleted axonal transport in the SC. Further experimentation is needed to determine whether such a mechanism is relevant in the models we explored.

CONCLUSIONS

Secondary degeneration of target sites in the brain is generally thought to be either concurrent with or just subsequent to the loss of primary input. We have shown using models of glaucoma that focal deficits in anterograde axonal transport from the retina to the SC induce a concurrent elevation of BDNF, especially in hypertrophic astrocytes, that is spatially coincident with the retinotopic location of transport loss. This elevation may reflect a local intrinsic pathway to slow loss of retino-collicular synapses, which are retained well after axonal transport is completely depleted by disease-relevant stressors.
ROLE OF THE FUNDING SOURCE

Supported by NIH EY017427 (DJC), the Melza M. and Frank Theodore Barr Foundation through the Glaucoma Research Foundation (DJC), a Departmental Unrestricted Award from Research to Prevent Blindness, Inc. (DJC), an American Health Assistance Foundation National Glaucoma Research Award (DJC), Fight for Sight (SDC), the Vanderbilt Discovery Science program (DJC), and Vanderbilt Vision Research Center (P30EY008126).

CONFLICT OF INTEREST

The authors have no conflicts of interest to disclose.

Acknowledgments—We thank Mrs. Ann Gearon and Mr. Brian J. Carlson for their assistance with intraocular pressure measurements.

REFERENCES


(Accepted 24 October 2012)
(Available online 14 November 2012)